Search Results

You are looking at 101 - 110 of 237 items for :

  • "neoadjuvant chemotherapy" x
Clear All
Full access

William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Matthew Goetz, Lori J. Goldstein, Clifford A. Hudis, Steven J. Isakoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena Moran, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda Telli, John H. Ward, Dottie A. Shead and Rashmi Kumar

BK Yang VQ Mougalian S . Neoadjuvant chemotherapy for breast cancer increases the rate of breast conservation: results from the National Cancer Database . J Am Coll Surg 2015 ; 220 : 1063 – 1069 . 6. Liedtke C Mazouni C Hess KR

Full access

J. Sybil Biermann, Warren Chow, Damon R. Reed, David Lucas, Douglas R. Adkins, Mark Agulnik, Robert S. Benjamin, Brian Brigman, G. Thomas Budd, William T. Curry, Aarati Didwania, Nicola Fabbri, Francis J. Hornicek, Joseph B. Kuechle, Dieter Lindskog, Joel Mayerson, Sean V. McGarry, Lynn Million, Carol D. Morris, Sujana Movva, Richard J. O'Donnell, R. Lor Randall, Peter Rose, Victor M. Santana, Robert L. Satcher, Herbert Schwartz, Herrick J. Siegel, Katherine Thornton, Victor Villalobos, Mary Anne Bergman and Jillian L. Scavone

Longhi A Ferrari S . Prognostic factors in non-metastatic Ewing's sarcoma tumor of bone: an analysis of 579 patients treated at a single institution with adjuvant or neoadjuvant chemotherapy between 1972 and 1998 . Acta Oncol 2006 ; 45 : 469 – 475

Full access

Margaret Tempero

. Tempero briefly discussed the A021101 pilot study at the University of California San Diego (NCT01821612). Patients enrolled in this single-arm phase II study received neoadjuvant chemotherapy (FOLFIRINOX) and capecitabine-based CRT followed by resection

Full access

Paul F. Engstrom

patients who receive neoadjuvant chemotherapy before resection of metastatic disease and the primary colon lesion, a shortened course of postsurgical chemotherapy should be considered. The section of the NCCN Guidelines on the Continuum of Care of Advanced

Full access

Hiram S. Cody III and Kimberly J. Van Zee

cancer . J Am Coll Surg 2000 ; 191 : 593 – 599 . 8 Breslin TM Cohen L Sahin A . Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer . J Clin Oncol 2000 ; 18 : 3480 – 3486 . 9 Dupont EL

Full access

Robert W. Carlson, Jillian L. Scavone, Wui-Jin Koh, Joan S. McClure, Benjamin E. Greer, Rashmi Kumar, Nicole R. McMillian and Benjamin O. Anderson

excellence in the United States. (See Table 3 for legend.) proposed for situations in which RT, brachytherapy, and/or surgery are unavailable. Examples noted in blue text include neoadjuvant chemotherapy or neoadjuvant chemoradiation performed in

Full access

Stuart A. Grossman, Susannah Ellsworth, Jian Campian, Aaron T. Wild, Joseph M. Herman, Dan Laheru, Malcolm Brock, Ani Balmanoukian and Xiaobu Ye

lymphopenia 2 months after beginning chemoradiation. 20 – 23 Notably, patients with stage III NSCLC who received neoadjuvant chemotherapy did not develop lymphopenia until they began treatment with radiation. 21 Relationships Between Severe TRL and

Full access

Bing-Yen Wang, Ping-Yi Lin, Shiao-Chi Wu, Hui-Shan Chen, Po-Kuei Hsu, Chih-Shiun Shih, Chao-Yu Liu, Chia-Chuan Liu and Yao-Li Chen

Sjoquist KM Burmeister BH Smithers BM . Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable esophageal carcinoma: an updated meta-analysis . Lancet Oncol 2011 ; 12 : 681 – 692 . 7 Courrech Staal EF Aleman BM Boot H

Full access

Marsha Reyngold, Joyce Niland, Anna ter Veer, Dana Milne, Tanios Bekaii-Saab, Steven J. Cohen, Lily Lai, Deborah Schrag, John M. Skibber, William Small Jr, Martin Weiser, Neal Wilkinson and Karyn A. Goodman

to 99% of patients receiving RT and only 53% of patients not receiving RT ( P <.0001). In the RT group, 21% received neoadjuvant chemotherapy only, 77% received both neoadjuvant and adjuvant, and 1% received adjuvant only. In contrast, among patients

Full access

Robert J. Morgan Jr., Ronald D. Alvarez, Deborah K. Armstrong, Barry Boston, Robert A. Burger, Lee-may Chen, Larry Copeland, Marta Ann Crispens, David Gershenson, Heidi J. Gray, Perry W. Grigsby, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Ursula A. Matulonis, David M. O'Malley, Richard T. Penson, Steven W. Remmenga, Paul Sabbatini, Russell J. Schilder, Julian C. Schink, Nelson Teng and Theresa L. Werner

, cholecystectomy, partial gastrectomy or cystectomy, ureteroneocystostomy, or distal pancreatectomy. 52 The therapeutic benefit of neoadjuvant chemotherapy followed by interval cytoreduction remains controversial (see next paragraph). 53 – 55 It may be